Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints

Treatments in Respiratory Medicine

Volumn 4, Issue SUPPL. 1, 2005, Pages 5-11

  Ambrose, Paul G ^a,b  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFALOTIN; CEFOTAXIME; CEPHALOSPORIN; CHLORAMPHENICOL; CLARITHROMYCIN; ERYTHROMYCIN; EVERNIMICIN; KANAMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; COMMUNICABLE DISEASE; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GEOGRAPHIC DISTRIBUTION; GOVERNMENT REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFORMATION DISSEMINATION; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PHARMACODYNAMICS; POLICY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL STANDARD; QUALITY CONTROL; REIMBURSEMENT; RESPIRATORY TRACT INFECTION; SENSITIVITY ANALYSIS; STANDARDIZATION; STREPTOCOCCUS PNEUMONIAE;

ADVISORY COMMITTEES; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CLARITHROMYCIN; GUIDELINES; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD;

EID: 16844382245     PISSN: 11763450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Wikler MA, Ambrose PG. The breakpoint. In: Lorian V, editor. Antibiotics in laboratory medicine. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2005: 1-7
2. Barry AL. Definition of terms "resistant" and "susceptible". In: Barry, AL, editor. The antimicrobial susceptibility test: principles and practices. Philadelphia (PA): Lea and Febiger, 1976: 12-29
3. Hansman D, Bullen MM. A resistant pneumococcus. Lancet 1967; 2: 264-5
4. Dudley MN, Ambrose PG. Monte Carlo PK-PD simulation and new cefotaxime, ceftriaxone, and cefepime susceptibility breakpoints for S. pneumoniae, including strains with reduced susceptibility to penicillin [abstract A-635]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
5. Ambrose PG, Craig WA, Bhavnani SM, et al.. Pharmacodynamic comparisons of different dosing regimens of penicillin G against penicillin-susceptible and -resistant pneumococci. In: Programs and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27-30; San Diego
6. Ambrose PG, Bhavnani SM, Jones RN, et al. Use of pharmacokinetic-pharmaco-dynamic and Monte Carlo simulation as decision support for the re-evaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae [abstract A-126]. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
7. Standardizing clinical microbiology. pathbreakers: a century of excellence in science and technology at the University of Washington. In: History of the Department of Microbiology of the University of Washington: the first twenty years in the New School of Medicine as viewed by the Departmental Chairman, Charles A. Evans 1987 [online]. Available from URL: http://www.washington.edu/research/pathbreakers/1960h.html [Accessed 2004 Oct 9]
8. Sherris JC. Antimicrobic susceptibility testing: a personal perspective. Clin Lab Med 1989; 9: 191
9. Bauer AW, Kirby WMM, Sherris JC, et al. Antibiotic susceptibility testing by a standardized single disc method. Am J Clin Pathol 1966; 45: 493-6
10. Griswold, et al. In the Supreme Court of the United States, October term 1968, No. 343. Brief for the United States. U.S. Government Printing Office, 1968
11. Ericsson HM, Sherris JC. Antibiotic sensitivity testing: report of an international collaborative study. Acta Pathol Microbiol Scand 1971; Section B, Suppl. 217
12. NCCLS. NCCLS history [online]. Available from URL: http://www.neels.org [Accessed 2004 Oct 10]
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests; approved standard. 8th ed. Document M2-A8. Wayne (PA): NCCLS, 2003
14. Fuch PC, Barry AL, Thornsberry C, et al. Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing. Antimicrob Agents Chemother 1980, 18: 88-93
15. Thornsberry C, Jones RN, Barry AL, et al. Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response. Rev Infect Dis 1982; 4 Suppl. S316-24
16. National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters. 2nd ed. Approved standard M23-A2. Wayne (PA): NCCLS, 2001
17. Quintiliani R. Pharmaceutical reimbursement policy and physician prescribing patterns: a case study of oral and injectable cephalosporins in Italy. Today's Therapeutic Trends 1997; 24: 245-50
18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100-S15. Wayne (PA): NCCLS, 2004
19. Drusano GL, Preston SL, Hardalo C, et al. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001; 45:13-22.
20. EUCAST definitive document E. Def 2.1, August 2000. Determination of antimicrobial susceptibility test breakpoints. Clin Microbiol Infect 2000; 6: 570-2
21. Kahlmeter G. Brown DFJ, Goldstein FW, et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003; 52: 145-8
22. Mouton JW. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 2003; 17: 579-98
23. Dudley MN, Ambrose PG. Pharmacodynamics in the study of resistance and establishing in vitro susceptibility breakpoints: ready for primetime. Curr Opin Microbiol 2000; 3: 515-21
24. Craig WA, Kiem S, Andes DR. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin [A-1264]. In: Programs and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy: 2002 Sep 27-30; San Diego
25. Patel KP, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40: 2375-9
26. Rodvold KA, Gotfried MH, Danzinger LH, et al. Intrapulmonary steady-state concentration of clarithromycin and azithromycin in healthy volunteers. Antimicrob Agents Chemother 1997; 41: 1399-1402
27. Noreddin AM, Roberts D, Nichol K, et al. Pharmacokinetic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother 2002; 46: 4029-34
28. Ambrose PG, Grasela DM. The use of Monte Carlo simulations to examine the pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000 Nov; 38 (3): 151-7